Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vancomycin and Tobramycin

Phase 3Small molecule

MMajor Extremity Trauma Research Consortium

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post Operative Surgical Site InfectionCompleted

Post Operative Surgical Site InfectionPhase 3

Completed

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Post Operative Surgical Site Infection

NCT04678154

Clinical

Trials by Indication[1]

Post Operative Surgical Site Infection2 trials

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2 - A Continuation of the Multicenter Randomized Control Trial SEXTANT 1

Recruiting·MMajor Extremity Trauma Research Consortium·Phase 3·NCT04678154·600 enrolled

Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)

Completed·MMajor Extremity Trauma Research Consortium·Phase 3·NCT02227446·1,036 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vancomycin and Tobramycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vancomycin and Tobramycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vancomycin and Tobramycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Major Extremity Trauma Research Consortium company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMajor Extremity Trauma Research Consortium

Related News